Loading organizations...
Growth Science Ventures operates as a venture capital firm leveraging advanced data science and artificial intelligence to identify strategic investment opportunities. The company employs proprietary infrastructure, including its Quannix platform, to meticulously analyze complex industrial and societal systems, pinpointing hidden patterns and critical bottlenecks. This analytical approach informs their capital deployment across sectors such as agriculture, healthcare, and energy, where systemic inefficiencies often hinder progress.
Thomas Thurston founded Growth Science Ventures in 2018, establishing the firm based on the insight that traditional investment strategies frequently overlook the intricate dynamics of value creation and movement within complex systems. Thurston's extensive experience, spanning nearly two decades of collaboration with global organizations, informed the development of a data-intensive methodology designed to reveal underlying systemic truths and leverage points for impactful investment.
The firm partners with companies facing real-world challenges, utilizing its analytical depth to guide investments and innovations. Growth Science Ventures aims to support ventures that address fundamental constraints, driving both commercial success and broader societal well-being. Their vision centers on continuous learning through real-world investment outcomes, translating sophisticated data insights into decisions that foster enduring value and progress.
GS Ventures has 4 tracked investments across 4 companies. The latest tracked deal is $4.8M Series A in RXC in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 7, 2026 | RXC | $4.8M Series A | — | Korea, LB Investment, Z Venture Capital |
| Nov 4, 2025 | Sovato | $41.0M Series B | Michael Gross, Beringea, Michael Gross | Intuitive Ventures, Laerdal Medical, Polaris Partners, Puma Venture Capital, Teladoc Health, Vitalize Venture Group, Laerdal, Polaris Partners |
| Jul 14, 2025 | Illimis Therapeutics | $41.8M Series B | Yohan KIM | AJU IB Investment, A Ventures, Company K Partners, Daily Partners, Hana Ventures, IMM Investment, Industrial Bank OF Korea, Korea Development Bank, LB Investment, Maple Investment Partners, Quad Investment Management, Schmidt, Shinhan Venture Investment, S&S Investment, TS Investment, Jiwoong Chun |
| Jun 29, 2023 | Levit | $46.0M Series B | DST Global | Daegwon Chae, KB Investment, Klim Ventures, Korea Investment Partners, Mirae Asset Capital |